COLORADO SPRINGS, Colo.,
March 19, 2014 /PRNewswire/ --
Cannabis Science, Inc. (NASDAQ OTC: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, applauds federal government approval of a
University of Arizona study of efficacy
of medical cannabis in treating post traumatic stress disorder
(PTSD). Cannabis Science sees this approval by the U.S.
Department of Health and Human Services as a watershed moment for
federal authorization of medical cannabis research.
"As a premier medical cannabis pharmaceutical company, we
welcome the federal government support of a significant patient
study of the effectiveness of treating PTSD with medical
cannabis. While admittedly a first step, it is a substantial
one that moves federal policy in the direction of permitting
important patient-based research that we at CBIS believe will show
the clear medical value of cannabis for many diseases and
conditions," said Dorothy H. Bray,
Ph.D., Director & CEO of Cannabis Science, Inc.
For more information about the approved study, please see the
following links:
http://www.techtimes.com/articles/4525/20140319/federal-government-shows-greenlight-for-medical-marijuana-study-for-ptsd-treatment-of-veterans.htm
http://news.yahoo.com/marijuana-study-veterans-wins-federal-163051558.html
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding
of metabolic processes to provide novel treatment approaches to a
number of illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history
dating back thousands of years, and currently there are a growing
number of peer-reviewed scientific publications that document the
underlying biochemical pathways that cannabinoids modulate. The
Company works with leading experts in drug development, medicinal
characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on skin cancers and neurological
conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries:
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
SOURCE Cannabis Science, Inc.